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ON THE ROLE OF VITAMIN D IN MULTIPLE SCLEROSIS 
DEREK EDWARD BOWMAN 
ABSTRACT 
Multiple sclerosis (MS) is among the most common neuroinflammatory diseases across the 
globe and is autoimmune mediated in nature. This progressive, highly debilitating disease 
often leaves individuals wheelchair bound within 15-25 years of onset. MS is characterized 
by inflammatory lesions that appear in unpredictable locations around the central nervous 
system. Lesions can be visualized using magnetic resonance imaging (MRI) technology. 
As neuroinflammation continues and lesions accumulate, patients can experience a wide 
array of progressively worsening symptoms including but not limited to motor 
impairments, sensory disturbances, loss of control of bodily functions, and/or neuropathic 
pain, depending on the location of lesion formations. There are different types of MS, the 
most common being relapsing-remitting MS (RRMS) seen in about 85% of cases and 
characterized by periods of symptom remission followed by flare-ups. A large majority of 
these patients go on to develop secondary progressive MS (SPMS) where neurological 
damage and patient decline is progressive and continuous. Primary progressive MS 
(PPMS) is seen in about 10% of cases and is characterized by progressive and continuous 
patient decline from the outset of disease. Other rarer forms of MS do exist but will not be 
discussed further. Research aimed at MS is at an all-time high and the timing could not be 




For decades MS has been thought of as a disease caused by dysfunctional CD4+ T-helper 
1 (Th1) cells. It is now known that many different cell types contribute to MS 
pathophysiology. These other cell types include macrophages and dendritic cells of the 
innate immune system due to their expression of MHC class II molecules that function to 
activate CD4+ Th1 cells. More recent research has implicated CD8+ T-cells and B-cells in 
contributing to disease through direct destruction of neural cells that express MHC class I 
molecules and through the generation of autoantibodies, respectively. While these 
discoveries are important and provide hope for future breakthrough treatments, there are 
still enormous gaps in the medical community’s knowledge of what causes MS.  
 
The epidemiologic pattern of MS prevalence has for many decades interested scientists and 
hinted at a potential cause of this disease. MS tends to affect white individuals with genetic 
ties to northern Europe, but this relationship may not still hold true, as MS incidence and 
prevalence may be rising faster in black populations compared to other races/ethnicities, at 
least in the United States. MS occurs nearly 3 times as often in females than in males and 
is strongly associated with Epstein-Barr virus (EBV) infection—especially in those that go 
on to develop infectious mononucleosis (IM). MS prevalence increases markedly in 
regions north of 40 degrees North latitude or south of 40 degrees South latitude. MS risk 
also changes depending on body mass index (BMI) considerations, migration history, and 
in families with a genetic history of the disease. It is well-accepted that MS has a genetic 
component, the most important of which is the presence of the HLA-DRB1*1501 allele 




unable to sufficiently account for MS risk as the concordance rate for identical twins with 
MS is only 25-30%. These well-established findings imply that some unknown 
environmental factor(s) must be contributing to MS initiation and progression. 
 
All of the environmental factors listed above have a common connecting thread that is 
logically and empirically verifiable: vitamin D. This fat-soluble vitamin can either be 
endogenously synthesized in the skin after exposure to ultraviolet B (UVB) light or 
consumed through the diet, the former being of more importance to humans. 
Epidemiologic patterns suggest a protective role for vitamin D in MS, where low or 
deficient levels of vitamin D may be a contributor to increased risk for MS. Populations 
living at greater latitudes, north or south, have significantly greater prevalence of MS which 
coincides with the reduction of endogenously produced vitamin D in these regions due to 
a lesser amount of UVB light (and of lower intensity) experienced year-round. Increases 
in BMI, especially increased adiposity, correlate with increased risk for MS and with 
prevalence of vitamin D deficiency. Women tend to naturally have greater adiposity than 
men, thus increasing their risk for MS. Estrogens and vitamin D have been shown to act 
synergistically to protect against MS, therefore vitamin D deficiency may increase risk for 
MS in women.  
Vitamin D is a known immunomodulatory agent that promotes tolerogenic immune states. 
Vitamin D also offsets many of the harmful effects caused by EBV, among these including 
repression of B-cell differentiation into plasma cells, reduced MHC II expression, and 




by B-cells. Vitamin D is also immunologically beneficial as it promotes regulatory T cell 
function and their expression of protective cytokines, and through its inhibition of 
inflammatory Th1 and Th17 cell functions. In total, the immunomodulatory mechanisms 
of vitamin D are important as the immunological states produced by vitamin D are exactly 
the opposite of those observed in MS patients and MS animal models. Research in vitamin 
D is gaining attention as the scientific community is quickly discovering that its true 
physiologic role extends far beyond its classical function as a calcium regulator. Indeed, 
rapidly evolving research is revealing roles for vitamin D in cardiovascular function and 
blood pressure regulation, brain development and neurological function, and even in the 
prevention of certain cancers. However, this thesis will focus on its most well-known 
function secondary to calcium regulation: immunomodulation and its anti-inflammatory 
capabilities. 
The last portion of this thesis will present information advocating for the increase in 
minimum dietary intake of vitamin D from its current value of 800 IU/day to 5,000 IU/day. 
While a more than 5-fold increase may seem drastic, the tolerable upper limit is at least 
10,000 IU/day even by the most conservative of estimates—the true upper limit is probably 
around 20,000 IU/day and may even be 50,000 IU/day. The global prevalence of vitamin 
D deficiency is so extensive that some authors have even considered it a global pandemic: 
upwards of 50% of the entire world population may be deficient in this crucial vitamin. 
Increasing vitamin D supplementation is an extremely low risk way to reduce risk for MS 
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Background of MS 
Multiple sclerosis (MS) is an incurable, progressively debilitating, chronic 
neuroinflammatory disease of the central nervous system (CNS) that is autoimmune-
mediated in nature with limited treatment options.1–3 Epidemiologic data suggests that MS 
arises due to environmental factors experienced early in life in individuals that are 
genetically susceptible to acquiring the disease.4 
MS is characterized by the destruction of both the myelin and axons of myelinated axons 
in unpredictable locations throughout CNS.1,2 The pathophysiological cause of this CNS 
destruction is the infiltration of immune cells from peripheral areas across the blood-brain 
barrier (BBB) and into the CNS tissues.1 After infiltration, autoreactive immune-cells 
promote “inflammation, demyelination, gliosis, and neuroaxonal degeneration, leading to 
disruption of neuronal signaling” and the overall formation of “lesions” on myelinated 
axons.1 Lesions, the areas of active immune dysfunction, can be visualized via magnetic 
resonance imaging (MRI) and are a hallmark of MS.1 It is generally accepted that MS is 
predominately a CD4+ T helper (Th) 1 cell mediated-autoimmune disease.3 However, 
other immune cells are certainly involved in important ways, yet much remains to be 
learned about these immune cells and the pathophysiology of MS as a whole.1,3  
Due to the stochastic nature of lesion location, timing, and severity, MS has a variable 
presentation that can include sensory disturbances, neuropathic pain, motor impairments, 
	 	 	
	2	
and/or cognitive deficits.1 Clinical symptoms are correlated with the location of the 
lesions.1 
Based on how the disease progresses, neurologists group patients into four main 
categories:2 
1) Relapsing-remitting MS (RRMS) is the most common, at 85% of patients 
exhibiting this form.1,2 It is characterized by an initial flare-up of symptoms, 
referred to as the clinically isolated syndrome (CIS), which is followed by 
ongoing phases of remission and relapse with no discernible pattern or 
timeframe.1,2 During the early course of the disease, patients generally fully 
recover from these flare-ups, usually without any major lingering deficits of 
function, but this is not the case for long.1 Flare-ups/relapses during this time 
coincide with white matter lesions.1 As the bouts of remission and relapse 
continue, lesions accumulate in the CNS with subsequent mounting deficits of 
patient functioning, with nearly 80% of these patients going on to develop 
secondary progressive MS.1 
2) Secondary progressive MS (SPMS), unlike relapsing-remitting, is no longer 
characterized by white matter lesions.1 Instead, patients experience continual 
progressive atrophy of brain volume, CNS axonal deterioration, and 
generalized worsening of symptoms with or without flare-ups.1,2  
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3) Primary progressive MS (PPMS) affects about 10% of all patients with MS.1,2 
In this form, patients experience a progressive decline from the start, without 
the typical relapse-remission phases.1,2 
4) Progressive-relapsing MS is a rarer form of the disease, with fewer than 5% of 
patients falling into this category.2 It is a particularly debilitating form where 
patients experience progressive deterioration from the onset of disease with 
additional flare-ups intermittently that exacerbate decline.2 
Other, even rarer forms of MS do exist, but they will not be explored further. Figure 1 
below shows visually the disease course of the three most common forms of MS.  
MS has an average onset at 30 years of age, with 50% of patients requiring permanent need 
of a wheelchair within 25 years of disease onset.1 Other sources report an even more rapid 
need for permanent wheelchair use at only 15 years post disease onset.2 Approximately 2.5 
million people worldwide have MS1 and in the United States alone some 250,000-350,000 
people are afflicted by the disease.2 MS affects women disproportionately more than men, 
with 2-3 times as many women than men having the disease.2,3 In the United Kingdom, 
MS is the most common cause of chronic, non-traumatic disability among young adults5 
and in developed nations generally, its socioeconomic impact in young adult populations 




Epidemiology of MS 
Analyzing epidemiologic data of any kind generally begins with the question of “How 
much of the disease is present?”. Statistical measures used to answer this foundational 
question are prevalence (total number of patients with the disease alive at a specified date 
per 100,000 population) and incidence (the number of new cases of disease per 100,000 
population per year). Using these metrics, it has been determined that MS is the most 
common demyelinating disease in higher income countries and its global median 
Figure 1. Various Forms of MS. The clinically isolated syndrome, a hall mark of relapsing-
remitting MS, is the first occurrence of clinically discernible MS symptoms and typically 
occurs around 30 years of age. Relapsing-remitting MS is the most common form of MS and 
as the name suggests, is characterized by periods of disease flare-ups and remissions. This 
form typically progresses into secondary progressive disease with continuing decline in brain 
volume and neuronal function. Primary progressive MS features progressive decline from the 
start without periods of relapses. Figure taken from (Dendrou et al., 2015). 
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prevalence continues to rise.6 From 2008 to 2013, the global median prevalence has risen 
from 30/100,000 people to 33/100,000.6 Considering the world population increased from 
about 6.8 billion people to 7.2 billion during that same time period,7 even seemingly minor 
increases in median prevalence actually represent a substantial increase in disease burden. 
Incidence of MS may also be increasing as well. A study analyzing MS incidence from 
1905-1984 revealed increasing MS incidence from 3.7 to 7.7 per 100,000 over this time 
period, with especially notable rises in women.4 Other studies have shown this rising 
incidence in women as well. In Denmark, a rising female to male sex ratio of MS patients 
has been noted since 1950, as shown below in Figure 2.8 Teasing apart real patterns of 
prevalence changes from other confounding factors like overall increases in survival time 
with the disease and greater diagnostic ability—which have both increased in most of the 
world over the past five decades—remains a persistent statistical issue when using 
prevalence and incidence metrics.8 Measurements using incidence, compared to 
prevalence, indicate changes in population risk sooner, are more independent of survival 
time and diagnostic/ascertainment accuracy issues, and are generally a better measure of 





Further analysis reveals that North America and Europe have the highest prevalence of MS 
at 140 and 108/100,000 population, respectively, while East Asia and sub-Saharan Africa 
have some of the lowest prevalence of MS at 2.2 and 2.1/100,000 population, respectively.6 
This geographic pattern of MS prevalence has fascinated investigators for nearly a century 
and is well documented, although its cause remains elusive.4 The phenomenon is depicted 
below nicely in Figure 3.  
Figure 2. MS Incidence Among Women Has Risen Disproportionately in Demark 
from 1950-1999. The female: male sex ratio for MS incidence has nearly doubled in 





The notable geographic distribution pattern of MS prevalence has spurred a few different 
hypotheses. Among the most studied are 1) the latitude at which high or low risk regions 
exist and 2) genetic differences between the populations that live in high or low risk 
regions.  
 
Figure 3. Geographic Pattern of MS Prevalence. The majority of North America and 
Europe are notable for their high MS prevalence while South America and Asia show much 
lower prevalence. Figure taken from (Milo & Kahana, 2010). 
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The Immune System and MS 
The immune system has multiple mechanisms in place to prevent autoreactivity. Among 
these include central tolerance in the thymus where developing T-cells are selected for (or 
against) and peripheral tolerance where through numerous mechanisms autoreactive T-
cells are removed, and suppression of autoreactive T cells by another type of T-cell, the 
regulatory T cell (Treg).9 Regarding self-reactivity and its regulation—or lack thereof—
there is a consensus that CD4+ T-cells play a major role in this process.9 
The most widely accepted hypothesis used to explain MS pathogenesis postulates that 
CD4+ T-cells become sensitized and autoreactive towards CNS-antigens somewhere else 
in the body, that is to say not in the CNS compartments.10 The support for this hypothesis 
regarding cell type comes from the observation that CNS-reactive CD4+ T cells are the 
only immune cells able to induce EAE when transferred to animals and that the strongest 
genetic risk factor for MS is the human leukocyte antigen (HLA) class II haplotype 
HLADRB1*1501, which associates with CD4+ T-cells.10 Peripheral activation of those T-
cells, as opposed to activation in the CNS, is supported by the concept of molecular 
mimicry. Molecular mimicry is the process whereby a foreign antigen (perhaps a viral 
peptide) so closely resembles a self-antigen that T-cells become activated against the 
foreign antigen and cross-react with the self-antigen, triggering MS flare-ups and other 
autoimmune diseases. A study Fujinami and Oldstone showed that immunization of rabbits 
with a hepatitis B virus peptide that shared a 6 amino acid sequence with myelin basic 
protein can induce EAE, thus providing support for the peripheral activation of T cells via 
molecular mimicry with subsequent CNS autoreactivity.11  
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There are distinct subsets of CD4+ T-cells that are relevant to MS: Th1, Th2, Th17, and 
regulatory T cells (Treg). For years interferon gamma (IFN-γ) secreting Th1 cells have 
been implicated as playing a central role in MS pathogenesis.12 This is because of all the 
CD4+ T-cells that may (or may not) play a role in MS, the Th1 subset are the most likely 
to become autoreactive against myelin proteins (MBP, MOG).10 This fact has driven much 
interest into studying this specific subset. However, many sources suggest this is an 
oversimplification of an incredibly intricate process.12 
Indeed, another important subset of cells, CD4+ Th17 cells promote inflammatory states 
via their secretion of interleukin 17 (IL-17) and interleukin 6 (IL-6).12 In animal models, 
Th17 cells were necessary for development of EAE and in MS patients, are highly present 
in active lesions.12 C-C chemokine receptor 6 present on Th17 cell surfaces allow transport 
through the choroid plexus and into the cerebral spinal fluid (CSF) where these cells may 
go on to secrete additional factors (IL-17, IL-22) that disrupt endothelial tight junctions 
and increase permeability of the BBB, allowing even further inflammatory cell access.12 
Presence of inflammatory T cells and cytokines in the CNS triggers additional recruitment 
of T cells, as well as B cells, dendritic cells, microglia, and natural killer (NK) cells.12 
Interestingly, CNS-antigen activated CD4+ Th1 cells, when transferred to recipient 
animals, initiate mainly spinal cord inflammation, while activated Th17 CD4+ cells 
promote brainstem, cerebellum, and brain inflammation.10 Overall, most evidence suggests 
CNS antigen-specific CD4+ T cells have an important role in initiating MS.10  
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While CD4+ T-cells are strongly linked to initiation of MS, new and mounting evidence 
indicates that continued CNS damage during relapses and in chronic phases is due to 
involvement of CNS antigen-specific CD8+ T cells.10 Axons and neurons only express 
major histocompatibility complex (MHC) class I molecules, therefore CD8+ T-cells can 
directly damage those structures, whereas CD4+ T cell mediated damage here can only 
occur indirectly.10 Indeed, axonal damage has been associated with an abundance of 
microglia and CD8+ T cells.12 Clonally-expanded CD8+ T cells are often copiously found 
in MS lesions adding additional weight to the hypothesis of their involvement in CNS 
tissue damage.10 However, CD8+ T cells in some studies, are found in lower frequencies 
in the circulation in patients with MS compared to healthy patients.13 Some hypothesize 
that this adds support to the Epstein-Barr virus (EBV) theory of MS (considered in more 
detail later). It is thought that because EBV is normally kept in check by CD8+ cytotoxic 
T (Tc) cells, lower frequencies of these cells may allow EBV to run rampant, thus allowing 
for the initiation or perpetuation of MS.13  
To complicate matters further, both CD4+ and CD8+ T cells can have variable function: 
some are pro-inflammatory, like CD8+ Tc17 that can secrete pro-inflammatory IL-17, 
while others have anti-inflammatory like the regulatory CD8+ FoxP3+ Treg cells.12,13 
FoxP3 is the transcription factor that is required for the development of both regulatory 
CD8+ Treg cells and CD4+ CD25+ Treg cells in the thymus.13,14 CD8+ FoxP3+ Treg cells 
have been shown to have significantly impaired suppressive functions during periods of 
relapse in MS patients regardless of their circulating frequencies.13 Likewise, a different 
study showed similar circulating numbers of Treg cells in MS patients and healthy 
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individuals, but Treg cells had reduced suppressive potential in MS patients.12,13 Studies 
have shown that compared to healthy individuals, MS patients had significant losses of 
CD4+ CD25+ Treg frequency and effector function, and reduced expression of 
transcription factor FOXP3.12 In mouse models, depletion or inactivation of Treg cells 
increases the susceptibility of EAE development, while the transfer of Treg cells into Treg 
deficient animals can prevent EAE development.13 An additional subset of important Treg 
cells are CD39+ Treg cells because they have the ability to suppress deleterious Th17 
cells.13 
It should be noted that FoxP3 expression in regulatory cells is lowest during relapsing-
remitting MS, but expression is recovered later during secondary-progressive MS.13 This 
provides support for differing pathophysiologic mechanisms between the different types of 
MS. Furthermore, Treg suppressive function and FoxP3 expression can (and should) be 
used as an important marker of MS progression clinically and academically.  
To summarize the previous T-cell topics, T-cells in regard to MS come in two general 
types: inflammatory or regulatory. Inflammatory T-cells, Th1, Th17, and Tc17 subsets, 
promote MS progression and secrete deleterious IFN-γ and IL-17. Growing evidence 
shows the importance of Treg cells in MS and convincingly shows that a lack of Treg 
function is associated with exacerbation of MS symptoms.  
New research in MS immunology continues to reveal exciting new discoveries: with as 
many as 95% of diagnosed MS patients showing presence of immunoglobulins in the CSF, 
arguments for potential roles of B cells are growing.12 Mechanisms by which B cells may 
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promote MS include secretion of proinflammatory cytokines, activation of autoreactive T 
cells through the roles as antigen presenting cells (APC), and production of myelin reactive 
autoantibodies when activated and subsequently differentiate into plasma cells.13 However, 
while myelin reactive antibodies have been observed, their importance has yet to be 
determined.12 Clinical monoclonal antibody therapies targeted against CD20 (found on B 
cells) have been found to reduce both the number of relapses and the generation of new 
lesions, thus providing support for a role of B cells in MS.13 These therapies have been 
thought to reduce B cell cytokine production and limit antigen presentation.13 Like the T-
cells, B-cells have an inflammatory subset and a regulatory (Breg) subset.13 Breg cells 
inhibit Th1 and Th17 cell differentiation and promote CD4+ Treg cells, but in patients with 
MS these Breg cells are reduced both in number and suppressive functionality.13 MS-
related research has only recently focused on the role B cells play and much remains to be 
known about this important subset of cells. 
In describing MS, medical language uses a preponderance of, for lack of a better term, 
“additive language”. Examples here include: an abundance of inflammation, development 
of new lesions, the presence of autoantibodies in the CSF, etc. These descriptors are of 
course true, clearly relevant to MS, and certainly important. However, with such a 
perspective it becomes easy to assume that the symptomology seen is solely caused by the 
addition of a deleterious agent e.g., a virus, a faulty gene, or some pernicious environmental 
exposure. It is important to remember that what is absent is often times just as important 
as what is present. For example, sentences require spaces between words to maintain their 
coherence—a lack of spaces would dash any chance at coherence just as the addition of 
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nonsensical words would. Similarly, perhaps MS is not caused solely by the addition of a 
foreign viral antigen or by the novel development of autoreactive immune cells, but in 
conjunction with a paucity of protective immunomodulatory mechanisms that exist in 
healthy individuals? 
Regarding MS, it is clear that what is missing are fully functional regulatory immune cells 
of both T and B cell lineage. These regulatory cells are charged with promoting self-
tolerance and an overall de-escalation of pro-inflammatory pathways. Dysfunctional 
regulatory cells are clearly implicated in MS, but the question remains on how these cells 
became dysfunctional in the first place. The answer to this important question would be 
even more profound if it could tie together major known risk factors, both genetic and 




Vitamin D Introduction 
Vitamin D is a fat-soluble vitamin that can be either endogenously produced in the skin 
upon exposure to sun radiation, specifically ultraviolet B (UVB) rays, or consumed from 
exogenous sources. Two main forms of vitamin D exist: the animal derived D3 
(cholecalciferol) and the plant derived D2 (ergocalciferol). Because vitamin D is found in 
relatively less abundance in natural foods, supplementation of vitamin D (either D2 or D3) 
in breads, milk, orange juice, and others has become common in the United States and 
other industrialized countries.  
Endogenous production of vitamin D3 in the skin is an enormously important process by 
which we maintain sufficient levels in the blood. In fact, it is the most important source of 
vitamin D in the body.15 In the skin, cholesterol is converted into 7-dehydrocholesterol. 
Upon irradiation from UVB rays, the conjugated double-bond structure of ring B of 7-
dehydrocholesterol is broken open, forming pre-vitamin D3. After a process called thermal 
isomerization takes place, formation vitamin D3 is complete (Figure 4). There is little-to-
no physiologic difference between vitamin D2 and D3, therefore vitamin D will be used 
nonspecifically in referring to these two molecules. An important caveat to vitamin D 
synthesis in the skin is its dependence on sufficiently intense ultraviolet irradiation. For 
example, from November to February in Boston (latitude ~42.2 degrees N), the intensity 
of UVB rays is insufficient to produce any vitamin D in the skin regardless of the duration 




In contrast, San Juan, Puerto Rico (latitude ~18 degrees N), UVB rays are strong enough 
to stimulate vitamin D production in the skin all year.15 Additionally, modern society has 
changed the environment where many people work (indoors) and how many commute to 
work (cars, busses). This means that if individuals are receiving sun during their working 
hours, it is probably through office and car windows. This poses a problem for vitamin D 
Figure 4. Synthesis, Metabolism, and Regulation of Vitamin D. Vitamin D can be 
synthesized endogenously or consumed through the diet. Two hydroxylations must take 
place in order for vitamin D to exert its physiologic actions, first at carbon-25 in the liver 
and second at carbon-1 in the kidney(s). Vitamin D homeostasis is complex and tightly 
controlled through a variety of negative feedback loops. Figure taken from (Holick, 2007). 
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production. Indeed, window glass filters out nearly 100% of UVB light, while still allowing 
ultraviolet A (UVA) rays to pass through.16 Since vitamin D production specifically 
requires UVB rays, which is blocked by window glass, many individuals are receiving less 
vitamin D-producing light than they may have thought.  
Once produced in the skin, vitamin D is not yet physiologically active. Before it can exert 
its physiologic effects, vitamin D must be hydroxylated at both carbon-25 and at carbon-1. 
These hydroxylations occur mainly in the liver and kidneys, respectively, but they can 
occur in other organs as well. Given its hydrophobic nature, vitamin D must be bound in 
the blood to a soluble carrier protein—vitamin D binding protein (DBP)—in order to leave 
the skin in any significant quantity. Exogenously consumed vitamin D is absorbed 
predominately in the jejunum as a micelle and has an overall absorption efficiency of about 
50%. After absorption in the intestines, vitamin D is incorporated into chylomicrons which 
make their way throughout the body, depositing fatty acids, cholesterol, and of course, 
vitamin D at hepatic and extrahepatic tissues.  
The DBP gene is the most polymorphic gene known with more than 1,200 polymorphisms 
currently listen in the NCBI database.17 There are more than 120 known variants of the 
protein and associations between various diseases and DBP variants have been reported, 
but the overall clinical significance remains unclear.17 
In the liver, vitamin D is hydroxylated by 25-hydroxylase (CYP2R1) to become 25-
hydroxyvitamin D (25(OH)D). Approximately 85% of 25(OH)D is bound to DBP, 15% is 
bound to albumin, and only 0.03% is non-bound.17 The major form of circulating vitamin 
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D is found as 25(OH)D and this form is also the most important biomarker used for 
determining vitamin D status.15  
After hydroxylation in the liver, 25(OH)D is transported to the kidney where 25(OH)D 
enters proximal tubule cells via receptor mediated endocytic internalization into proximal 
tubule renal cells and is hydroxylated at carbon-1 by 1-alpha-hydroxylase, or CYP27B1, 
to 1,25 dihydroxy vitamin D (1,25(OH)2 D).15  
25(OH) D has a half-life of 15 days in circulation, while 1,25 (OH)2 D has a half-life of 
10-20 hours, vitamin D’s whole-body half-life is roughly 2 months in the tissues.18  
25(OH) D only occupies 2-5% of DBP binding capacity. 25 (OH)D and certain inactive 
metabolites bind DBP with the same affinity, whereas active 1,25 (OH)2 D3 binds with an 
affinity an order of magnitude less.18  
1,25(OH)2 D exerts its physiologic action via the intracellular vitamin D receptor (VDR), 
a member of the nuclear hormone receptor family. VDR is a transcription factor that after 
binding with 1,25(OH)2 D, heterodimerizes with other nuclear hormone receptors. The 
heterodimer complex goes onto regulate gene transcription by binding to vitamin D 
response elements (VDRE). There exist thousands of VDREs among several hundred 
genes and it is thought that not all VDR-mediated actions require 1,25(OH)2 D binding. A 
good example of this is the hair loss seen in animals and subjects with VDR mutations but 
not in those with mutations in the enzyme responsible for producing 1,25(OH)2 D. 19 VDR 
is a ubiquitous protein found in nearly every type of tissue and in conjunction with 
1,25(OH)2 D, it modulates a variety of genes depending on the tissue. Indeed, 1,25 (OH)2 





The most well recognized role for VDR is maintenance of calcium homeostasis, but it also 
has extremely important roles in cellular growth and differentiation of the skin, pancreas, 
bone, and immune system.21 As we will see, vitamin D is connected to nearly every other 
major risk factor for MS.  
Figure 5. Activated Vitamin D Has Many Physiologic Functions. Far from a one trick 
pony, 1,25 (OH)2 D regulates a great number of peripheral tissues and exhibits a multitude 
of functions. Among these include cardiovascular, neurological, and immunological. Figure 





The objectives of this thesis are as follows: 
 
1. Review of literature on vitamin D studies regarding EAE and MS. 
2. Review of literature on the relationship between vitamin D and the major 
genetic and environmental risk factors for MS. 
3. Review of literature to determine the mechanistic role vitamin D plays in the 
immune system. 
4. Investigation of vitamin D toxicity and daily vitamin D intake maximums 
5. Conclusion on the efficacy and safety of increasing the minimum daily intake 





Objective One:  
The association between low levels of vitamin D and increased risk for MS has been known 
for some time.22 To determine if this association may reveal a mechanism that can be 
exploited for possible treatments, many studies have been conducted on both the safety and 
efficacy of vitamin D as a treatment in EAE animal models and MS patients.  
Low levels of 25(OH)D, ~20 ng/mL, are usually observed in MS patients at the CIS, 
although normal serum levels (30 ng/mL) are sometimes observed too.22 Using blood 
samples from more than 7 million US military personnel, Munger et. al found that serum 
25(OH)D levels greater than ~100 nmol/L (40 ng/mL) was associated with a 62% lower 
chance of developing MS.23 Lower serum concentrations of 25(OH)D are found during 
periods of MS relapse than during times of remission.24 Compared to healthy individuals,  
relapsing-remitting MS patients had reduced serum levels of 25(OH)D and 1,25(OH)2 
vitamin D, but no such difference was observed in primary progressive MS patients.24 This 
supports the concept of separate processes driving RRMS versus SPMS, and also helps 
explain PPMS where no relapses occur.1 These studies are useful in highlighting what 
appears to be an inverse relationship between vitamin D levels and MS risk, i.e. greater 
levels of vitamin D reduce MS risk, while lower levels increase risk. 
Vitamin D and EAE 
Experimental autoimmune encephalomyelitis (EAE) is the most common experimental 
model for MS25,26 and is the best understood.26 Animals (typically mice and rats) are 
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immunized with myelin peptides or myelin reactive T cells are transferred into the animals. 
These procedures induce a T cell mediated autoimmune reaction against CNS myelin and 
ultimately cause signs and symptoms that closely mirror those seen in MS patients.12 In 
EAE animal models, known myelin proteins like myelin basic protein (MBP) and myelin 
oligodendrocyte glycoprotein (MOG) can be used relatively easily to induce MS-like 
symptoms. In humans, however, common myelin antigens are still unknown in spite of 
many attempts of identify them.12 
The inflammation, demyelination, axonal loss, and gliosis that occur in EAE approximate 
that seen in MS, as do the resolution and remyelination processes.25 Many, but not all, of 
the drugs currently in use for treating MS have been developed through the use of EAE 
models.25 Even still, all immunomodulatory drugs approved by the FDA for MS are 
effective to some degree in treating EAE.26 This is a strong indicator of EAE’s validity as 
a model for MS.  
EAE animal models have been used to test the effect vitamin D supplementation has on 
disease severity and incidence. It has by in large been established that vitamin D deficiency 
decreases time to EAE onset and increases severity of symptoms.24 
Likewise, dietary vitamin D when consumed in high doses has been found to reduce EAE 
symptoms in mice. High-dose dietary vitamin D in combination with IFN-β (a “first line 
treatment for multiple sclerosis”), was found to reduce EAE symptoms in mice more 
effectively than either IFN- β treatment alone or dietary vitamin D alone.15 It is notable that 
the group receiving only high-dose vitamin D had cumulative disease scores nearly 
identical to the group receiving both IFN-β and low dose vitamin D. This is depicted below 
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in Figure 6. While the data spread is large in each group, the protective trend of increasing 
vitamin D intake is obvious and provides a rationale for continued study of combinatory 




Figure 6. Synergistic Effect of Dietary Vitamin D and IFN-β in Attenuating EAE 
Symptomology. EAE symptoms were more effectively reduced with use of both dietary 
vitamin D and IFN-β. High dose dietary vitamin D was more effective in reducing EAE 
symptomology than low dose vitamin D. Figure taken from (Christakos et al., 2016). 
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Spach et al. in 2005 pre-fed mice a vitamin D diet three times higher than a standard diet 
for 4 weeks prior to EAE induction. Compared to the control mice that had not received 
any vitamin D, the vitamin D fed female mice experienced significantly reduced severity 
of paralytic disease symptoms, histopathological and immunological signs of disease, but 
not the males. When females were ovariectomized, the vitamin D -induced protective effect 
was removed.27 A follow up study by Nashold et al. in 2009 showed that when 
ovariectomized female mice were supplemented with 17-beta-estradiol (E2) the vitamin D 
mediated protection returned and that E2 alone did not confer EAE protection.28 These 
results indicate a synergistic relationship between estrogen and vitamin D that is protective 
in nature. This relationship may be explained in part by the finding that E2 upregulates 
transcription and expression of VDR in many cell types and increases their responsiveness 
to 1,25(OH)2D.29 However, this seems to contradict the prevalence patterns of MS in 
humans, with women comprising 2-3x more of the total MS cases. 
Adzemovic et al. showed in 2013 that high dose vitamin D (10 IU/g food) fed to juvenile 
rats 4-5 weeks prior to EAE induction showed significant reduction in clinical disease, 
histopathological, and immunological signs compared to normal (2 IU/g food) or vitamin 
D deficient diets (these latter two groups did not differ significantly). This protective effect 
was not seen in adult rats. However, EAE was induced in juveniles at 8 weeks of age, while 
adults were induced at 20 weeks of age.30 Regardless, this study hints at a possible 
protective role for vitamin D in youth, which matches epidemiologic data from migrant 




Vitamin D and MS: 
 
Because of the low risk and moderately promising results of vitamin D supplementation in 
rats, vitamin D supplementation is being studied in human MS patients. 
In a one-year, double blinded, placebo controlled randomized study of 66 MS patients 
being treated with interferon beta (IFN-β) -1b, Soilu-Hanninen et al. in 2012 reported that 
compared to placebo (n=32), those receiving 20,000 IU (500 ug) vitamin D3 per week 
(n=34) had significantly reduced T1 enhancing lesions (p=.004), and reduced disability 
accumulation and improved timed tandem walk, although these did not reach statistical 
significance (p=0.071 and p=0.076, respectively). No difference in relapse rates or adverse 
events were seen, but the authors concluded that vitamin D3 as an add-on treatment to IFN-
β -1b reduced MRI disease activity.31 In a study by Mosayebi et al. in 2011 reported that a 
6 month-long, randomized, placebo controlled trial with 62 MS patients, 26 of whom 
received 300,000 IU/month vitamin D3 via intramuscular injection showed no significant 
differences in clinical disability scores or in number of gadnium-enhancing lesions, but the 
vitamin D treatment group did have significantly higher levels of TGF-β1 and IL-10, which 
have been shown to be protective against MS.32 In another study showing similar results, 
Hupperts et al. in 2019 investigated the effect of using 14,007 IU/day vitamin D 3 as an 
add on treatment to IFN-β -1a treatment in 229 RR MS patients (113 with D, 116 without) 
over 48 weeks. In this double blinded, placebo controlled randomized trial, the data showed 
no significant differences in clinical symptomatology of MS, but did report significantly 
better MRI data for the vitamin D group.33 In sum, the these studies show that vitamin D 
supplementation may not be the enough to significantly reduce MS symptoms, but it has 
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some protective functions as shown by the reduction of lesions and increases in protective 
cytokines. 
To address weaknesses of other trials (short duration and/or limited participants), Camu et 
al. in 2019 conducted a 2-year, double blind, placebo-controlled study with 181 relapsing-
remitting MS patients that were randomized 1:1 to placebo or 100,000 IU vitamin D every 
other week for 96 weeks. Only 45 patients in each group completed the 2-year follow up 
that showed significantly reduced annualized relapse rates, new T1-weighted lesions, and 
lower progression of expanded disability status score. The 100,000 IU treatment was well 
tolerated and adverse events were balanced between groups.34 This last study is much more 
promising in that it reduced relapses, MRI lesions, and even reduced disability. However, 
only half of the patients were retained thus creating a weakness in the study it hoped to 
avoid from the outset. This study highlights the safety and probable protective role vitamin 
D plays in MS risk.  
1,25 D and EAE:  
While the previous studies have been centered around vitamin D supplementation, other 
studies have tested the efficacy and safety of activated vitamin D, 1,25 (OH)2 D, on EAE 
animal models. A study by Lemire and Archer from 1991 showed that intraperitoneal 
administration of 1,25 (OH)2 D of 0.1 ug every other day beginning three days prior to EAE 
induction reduced both incidence and severity of disease. Hypercalcemia was observed, 
however.35 In a 1996 study by Cantorna et al., mice fed high calcium diets were either 
mocked treated or given injections of 1,25 (OH)2 D. Treatment with 1,25 (OH)2 D was 
shown to completely prevent EAE development and prevented progression of EAE when 
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administered on the first day of symptoms, these effects were reversed when 1,25 (OH)2 D 
was removed. However, doses of 1,25 (OH)2 D high enough to reach these effects resulted 
in hypercalcemia.36 Another study by Cantorna et al. in 1998 found that a daily diet of 1,25 
(OH)2 D (50 ng for female, 200 ng for males) administered one day before EAE induction 
completely prevented the onset of the disease and that intraperitoneal injection of 300 ng 
1,25 (OH)2 D at the peak of EAE symptoms rapidly attenuated the disease. This study also 
found significant increases in transcripts for anti-inflammatory cytokines interleukin 4 (IL-
4) and transforming growth factor beta 1 (TGF-β1). Serum calcium was only slightly 
elevated in treatment groups.37  
Dietary calcium may be an important factor as another study by Cantorna et al. showed 
that a given dose of 1,25 (OH)2 D shown to be 100% percent effective in preventing EAE 
symptoms at adequate calcium diets was only 50% effective in no calcium diets. Overall, 
they found that mice receiving lower calcium diets required more 1,25 (OH)2 D to prevent 
EAE symptoms.38 However, even in the low calcium diets hypercalcemia ensued.38  
 
While 1,25 (OH)2 D may indeed be a potent protective agent and possible treatment for MS 
as shown by EAE studies, the side effect of hypercalcemia hinders its use in clinical 
settings. Overall, there seems to be a general consensus that both vitamin D 
supplementation and 1,25 (OH)2 D do indeed have some protective effects against EAE 
and probably in MS. As reviewed by Christakos et al., whether vitamin D supplementation 




Genetic Factors in MS 
Support for a genetic link to MS are supported by familial groupings of disease, racial and 
ethnic patterns, and genomic studies.  
There are clear genetic associations in the risk of acquiring MS. Individuals with first 
degree relatives with the disease are some 10-25 times more likely to develop MS 
compared to the general public.39 More support of a genetic component in MS stem from 
greater concordance between monozygotic twins compared to dizygotic twins.39 A study 
assessing concordance rates of MS in siblings found that concordance rates were 25.3% ± 
4.4 for identical twins, 5.4% ± 2.8 for fraternal twins, and 2.9% ± 0.6 for nontwin siblings.40 
Monozygotic twin concordance is often cited at around 25-30%4,41, but other authors of an 
extensive twin study review in MS heritability suggest that the true concordance rate may 
be lower, suggesting that genetic components may contribute less than they are currently 
thought to.42  
 
Table 1. Familial Risks for Multiple Sclerosis. Taken from (Cree, 2014). 
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MS disproportionately affects women more than men and whites more than blacks. MS has 
historically had significantly higher incidence and prevalence in white individuals 
compared to people of other ethnicities.5 There is a high prevalence of MS in Europe, 
especially in the Scandinavian countries, as well as in Canada and the United States which 
received the majority of its early immigration from Europe.4 White individuals account for 
a significant portion of the populations of these countries. In countries with a mix of white 
and non-white natural born citizens, the white individuals nearly always have a higher risk 
for MS.5  
Average annual age-adjusted MS mortality rates per 100,000 in the U.S. was 0.90 for white 
males and 1.50 for white females, compared to 0.75 for black males and 1.42 for black 
females.43 Studies that have controlled for confounding factors show approximately a 40% 
reduction in MS risk in black individuals compared to white individuals.39 However, this 
data came from a study by Kurtzke et al. published in 1979, which may outdated as new 
data indicate the racial disparity of MS-mortality rates seems to be shrinking, as shown by 
Figure 7. Keeping with the historical trend, however, a recent study from 2017 that 
examined MS prevalence in east London found that compared to whites, the prevalence of 
MS is lower among blacks and south Asians, at 59% and 84% less, respectively.5 
Interestingly, rates of MS are significantly elevated in London residing blacks and south 
Asians (74 and 29/100,000 people), a temperate climate north of 40 degrees latitude, 
compared to ancestral territories of the sub-Saharan African country Ghana at .24/100,000 
people or south Asian countries of India and Pakistan at 7 and 5/100,000.5 This latter point 
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indicates an environmental factor that changes risk for MS, especially in populations that 
were historically low-risk for MS.  
While many studies highlight a decreased risk for black people, studies from MS patients 
in the United States show that this may not be so cut-and-dry, as incidence of MS may be 
rising in this population.44 A study by Langer-Gould et. al. in 2013 identified 496 newly 
diagnosed MS patients enrolled in the Kaiser Permanente South California health plan from 
2008-2010. This study found that compared to whites, the incidence of MS was higher in 
blacks and lower in Hispanics and Asians.45 It also found that the female bias of MS was 
more pronounced in black women and the total risk for MS in black women was higher 
than whites, whereas black men had non-significant differences in risk.45 An additional 
study from 2012 analyzed 2691 MS patients that served in the military from 1990 – 2007. 
Figure 7. Age-adjusted MS Mortality Trends by Sex and Race. Trends seem to be 
relatively constant with the exception of blacks and American Indians or Alaska Natives 
(NH AIAN). The rises in mortality are most notable in females. Figure taken from 





This study showed that the relative risk for MS in blacks is 27% greater than whites and 
that women have more than three times the risk of developing MS than men, irrespective 
of race.46 Greater inclusion of black individuals in research studies, reductions in 
segregation, and changing socioeconomic patterns in recent years may account for the 
increases seen in black populations. Whether incidence is increasing because of greater 
representation of black individuals in research studies or due to changing exposures 
remains to be fully understood. It seems unlikely that changing genetics would be the 
reason as one or two generations would not be enough time to account for these increases. 
As darker skinned individuals tend to produce less vitamin D through the skin in a given 
amount of time compared to lighter skinned individuals, and as vitamin D seems to have 
some protective roles in MS, perhaps low vitamin D levels could help explain these 
findings.  
An important and well-known genetic link for risk of MS are genes involved in encoding 
human leukocyte antigens (HLAs) for the major histocompatibility complex (MHC).6 
Specifically, the most significant genetic component seems to be the HLA-DRB1*1501 
allele that accounts for 11% of the heritability of MS.47 In fact, a genome-wide linkage 
screen conducted by the International Multiple Sclerosis Genetics Consortium revealed 
that the only statistically significant genetic linkage to MS was the MHC, with most of the 
associated risk driven by the HLA-DRB1*15:01 allele that codes for certain MHC 
proteins.48 Recent estimates from 2013 indicate that carriers of the HLA DRB1*1501 allele 
are three times more likely to develop MS than non-carriers.17 While the HLA-
DRB1*15:01 allele is the most important genetic factor driving risk, the HLA-A*02:01 
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allele is the principle driving protective allele.48 Parenthetically, there is a vitamin D 
response element (VDRE) in the promoter region of HLA-DRB*1501.47 The existence of 
a VDRE in the most important genetic region related to MS is an interesting finding, if not 
somewhat suggestive of a role for vitamin D in MS.47  
Another interesting observation on MS risk is a phenomenon referred to as the maternal 
“parent-of-origin” effect, the cause of which remains to be fully understood. There are 
strong epidemiological data showing how maternal half-siblings have almost double the 
risk of developing MS compared to paternal half-siblings (2.35% v. 1.31%, p=0.048), 
while maternal half-siblings have no significant difference in risk compared to full 
siblings.39 Given that a large percentage of an individual’s mitochondria originate from the 
mother and that there may be a possible risk associated with maternally-related individuals, 
could mitochondrial dysfunction be the driving factor in MS?  
Building evidence suggests mitochondrial dysfunction is indeed involved in MS.49 
However, it remains to be determined if the mitochondrial dysfunction observed is just 
another one of the many risk factors associated with MS, a side-effect from other causative 
factor(s), or perhaps the causative factor itself. As the mitochondria is an immensely 
intricate and complex organelle with cellular functions too numerous to detail fully here, 
no further discussion on this topic will take place.  
While a variety of genetic components are acknowledged, autoimmune diseases like MS 
cannot be solely explained by genetic make-up—environmental components must also 
play an important role.50 Indeed, the findings of increased risk for MS in ethnicities that 
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live in London compared to the same ethnicities that live in ancestral homelands strongly 
indicate that there is more at play than just similar genetics. Likewise, while twin studies 
show a considerable concordance rate of ~25% and provide a compelling argument to show 
a genetic component in MS, they simultaneously reveal that genetics alone are not 
sufficient to explain autoimmune disease. 
Many environmental factors have been examined to help explain autoimmune disease. 
Infectious agents, diet, chemical exposure, stress, and more have implicated in 




Environmental Factors in MS  
Several environmental factors have been implicated in increasing risk for MS. Of these 
environmental factors the most noteworthy are greater latitudinal distance from the 
equator, either north or south, vitamin D serum concentrations, infection with the Epstein-
Barr virus, and BMI. Another puzzling “environmental” risk factor to consider is biological 
sex. While not an environmental factor in the typical sense that refers to the external 
environment, males and females differ considerably in their internal environment, 
especially hormonally. 
Latitude and Geography and Migrant Studies  
 
The importance of a country’s latitude in risk for MS becomes especially obvious in 
Europe. More northern countries like Sweden, Norway, and even the United Kingdom, 
have a higher incidence of MS than do the Mediterranean countries of Italy, Greece, and 
Spain.6 There is a higher incidence of MS in latitudes greater than 40 degrees north or 
south.51 Indeed, in regions within the 40th parallel boundaries MS incidence ranges from 
57-78 cases per 100,000 people, whereas outside of these boundaries the incidence nearly 
doubles to 110-140 cases per 100,000 people.51 Living below 35 degrees north latitude for 
the first 10 years of life has been estimated to reduce the risk of multiple sclerosis by about 
50%.52 This is noteworthy given that sunlight exposure is the most important contributor 
to vitamin D levels.53 More northern latitudes tend to experience less sunlight year-round 
and of the sunlight they do receive, it tends to be of lesser intensity. Taken together this 
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means that residents of more northern regions will tend to produce less vitamin D than their 
southern counterparts and therefore may be at higher risks for MS.  
Greater sun exposure (averaging 2-3 hours more than controls) between the ages of 6-15 
years has been associated with lower risk of MS.4,54 Further support comes from a study 
by Goldacre et al. that showed sunlight-related skin cancers were significantly less 
common in MS patients compared to controls, implying that receiving less sunlight is 
protective against developing certain skin cancers but simultaneously increases the risk for 
developing MS.4 Ultraviolet radiation has been shown to reduce Th1-mediated immune 
responses, of which is a major feature of MS immunopathology.4 In a study considering 
the effect of UVB light in EAE mice and MS patients found that UVB phototherapy 
enhanced induction of Treg and tolerogenic dendritic cells and downregulated Th17 
generated IL-21 expression, which inhibits Treg generation. By the end of this treatment, 
serum 25(OH)D in humans increased from 14.04 ± 3.21ng/ml to 41.54 ± 3.92 ng/ml, p= 
.0001, but not in mice.55 Over the study period, no changes in relapse rate, neurological 
status, disability score, or MRI changes were observed, but this could be because of the 
short timeframe of the study (5 UVB light treatments per week for 6 weeks).55 While MS 
symptoms may not have improved in such a short time frame, the underlying immune 
system did seem to be altered positively, providing support for an protective mechanism 
induced by vitamin D. In a randomized, clinical trial involving 20 participants that had 
experienced the CIS in the past 120 days, half were assigned to receive 24 session of 
narrowband UVB exposure over 8 weeks while the other half did not. This trial showed 
that 100% of the no phototherapy participants compared to 70% of the phototherapy arm 
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had converted to MS.56 This difference was not significantly significant, however.56 A 
subsequent study in the same cohort showed that there were significantly higher frequency 
of naïve B cells (known to be increased during remission in MS and produce more IL-10 
than memory B cells), but no effects on FoxP3+ Treg, DC, or NK cell frequencies were 
detected after 24 sessions (3 per week, 8 weeks) in the phototherapy arm.57 
A study by Ramagopalan et al. from 2011 considered the relationship between UVB 
exposure, infectious mononucleosis (IM) due to EBV, and multiple sclerosis prevalence. 
They found that 61% of the variance in MS prevalence across England could be explained 
by UVB exposure (latitudinal effect) the distribution pattern of MS across England and by 
incorporating IM into their model 72% of the variance in MS could be explained.58 A study 
from 2013 showed that both narrow-band and broad-band UVB light, but not UVA, were 
able to significantly reduce the incidence of EAE, without increasing 1,25 (OH)2 D3 
levels.59 Narrowband light is currently being used to treat plaque psoriasis successfully60 
and safely.61 
High altitudes are associated with lower prevalence of MS and may arise due to greater 
intensity ultraviolet rays that correspond to higher altitudes.62 In Switzerland, greater rates 
of MS occur at low altitudes and lesser rates of MS occur at high altitudes which is thought 
to exist because of increased UV intensity at greater altitudes.62 In Norway, MS prevalence 
is lower along the coasts of Norway, where more fish is consumed, compared to higher MS 
prevalence found in inland populations.62 Fish oils are a rich source of vitamin D3 and their 
consumption is thought to be the driving factor in the observed prevalences.62  
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One of the most convincing studies supporting a protective effect of vitamin D on MS 
development risk was done by analyzing data from the Nurses’ Health Study (92,253 
women, 1980-2000) and the Nurses’ Health Study II (95,310 women, 1991-2001). 173 
cases of MS were confirmed from in these studies. Analysis of these studies showed that: 
1) comparing women in the highest quintiles of total vitamin D intake to the lowest quintile 
showed an age-adjusted relative risk (RR) of 0.67 and 2) the RR of intake of vitamin D 
supplements greater or equal to 400 IU/day compared to no supplements was 0.59.63 
Another interesting point for the importance of vitamin D in MS risk comes from the 
“month-of-birth” phenomenon. It is unique in that it postulates a possible in-utero effect of 
vitamin D. Data show that those born in autumn have a decreased risk of developing MS 
while those born in the spring have an increased risk. A study looking at individuals north 
of the equator estimated that those born in May had a 9.1% higher than expected risk of 
developing MS, while those born in November had a 8.5% lower than expected risk.39 This 
effect is even more dramatic in Scotland, where April sees 31% more MS births and 
November sees 20% fewer MS births.64 
For individuals born in November, they must have been conceived roughly nine months 
previously in February. This means that most of the pregnancy would occur during the 
summer months, when UVB rays are more intense, resulting in greater vitamin D 
production in the skin and subsequently higher levels of vitamin D in the blood that the 
fetus is exposed to. In contrast, individuals born in April/May must have been conceived 
around July/August. In these cases, most of the pregnancy would occur during the winter 
months, when UVB rays are less intense, resulting in lesser vitamin D production in the 
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skin and subsequently lower levels of vitamin D in the blood that the fetus is exposed to. 
This finding implies that an individual’s risk for developing MS is greatly influenced by 
factors experienced at a young age—and in this case, factors experienced in-utero. 
 
The environmental conditions where one is born and where they go on to live are also 
important factors in determining MS risk. Migration studies clearly demonstrate the 
importance the environment plays and are useful in determining patterns of MS 
development risk. A case-control study from 1985 analyzed the birthplace and service 
location for white veterans with multiple sclerosis. The study revealed that U.S. veterans 
that were born in northern regions, but served in southern regions had reduced their risk of 
developing multiple sclerosis by half, but still had a higher risk than those born in southern 
regions that also served in southern regions.65 Likewise, migrant studies convincingly show 
a reduction of MS risk in migrants from areas of high MS prevalence to low prevalence 
regions, and from areas of low prevalence to high prevalence showed an increase risk.66 
The figure below shows the strong pattern of risk reduction when migrating from high 




The reduction in risk as depicted in Figure 8 shows a compelling relationship between 
migration from high prevalence regions to low prevalence regions. This implies an 
underlying environmental factor that reduces the likelihood of MS in the low prevalence 
regions. Showing the opposite relationship, or an increase in MS risk, after moving from 
low to high prevalence regions would create an even more compelling argument—and 
indeed there is such a relationship. While there is in fact an increase in risk of MS for low-
to-high migration, the effect is not as strong as the reduction in risk seen in high-to-low 
Figure 8. Reduction in Multiple Sclerosis Prevalence Rate with Migration. The 
prevalence of MS is reduced through migration from a country with high risk for MS 
to a lower risk country. High risk countries indicated here are located in Europe and the 
British Isles, all of which are located at latitudes greater than 40 degrees North. Low 
risk countries indicated here are located between 40 degrees North and South latitudes. 
Figure taken from (Gale & Martyn, 1995). 
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migration.66 There is also an age-effect that is important to consider in these migrant 
studies. The reduction in risk obtained by high-to-low prevalence migration was greatest 
in those under the age of 10.66 In contrast, individuals that were born in low prevalence 
areas retained their low risk regardless of the age at which they move to an area.66 For 
example, adults from countries with low prevalence of MS (West Indies), that immigrate 
to Europe, a high-risk region, retain their low risk for developing MS.67 However, the 
children of those same immigrants are at high risk, unlike their parents.67 
These studies nicely illustrate the important role environmental factors play throughout 
life, especially on children and young adolescents. It is well established that a latitude 
gradient exists in MS and that UVB intensity declines in more northern or southern 
latitudes. Taking a look at Figure 8, all of the high prevalence regions listed are higher 
latitude than all of the lower prevalence regions. It seems likely that the environmental 
exposure that changes MS risk through migration is cutaneous vitamin D generation 
through UVB exposure. Considering the month-of-birth effect, the greater reduction in risk 
in migration studies for those younger than 10 years, and the difference in risk between 
migrant parents and their children all hint that vitamin D is an important factor to consider 
in younger individuals. This is possibility is supported by month-of-birth effect, where in 
utero exposure to vitamin D (or lack thereof) may contribute too. As there are no known 
cures for MS and no vaccinations available for the highly MS-associated EBV, vitamin D 
supplementation is a possible therapeutic avenue that may be beneficial in mitigating 
elevated MS risk inherent to certain regions. 
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Body Mass Index (BMI) 
Obese patients have a clearly increased risk of developing MS and are more prone to 
develop autoimmune diseases in general, typically experiencing more severe symptoms 
with these diseases as well.68 Both obesity and MS prevalence are rising, albeit at different 
rates (the former being much higher). The World Health Organization reported that in 2016 
about 13% of the world’s adult population was obese (11% of men and 15% of women) 
and that 39% of adults were overweight (39% of men and 40% of women).69 Aside from 
the slight increases in global obesity among women compared to men, women also have a 
higher percentage of body fat, in general.70  
A study considering obesity and MS disability scores found that obese RR-MS patients 
showed higher clinical disability, increased CSF pro-inflammatory cytokines (IL-6 and 
leptin) and reduced concentrations of anti-inflammatory cytokines including interleukin 13 
(IL-13).71 
A study using 309 relapsing-remitting MS patients and 322 controls found that excess 
weight at age 15 and obesity at age 20 increased the odds of developing MS by a factor of 
2.16 and 3.9, respectively. It was found that leptin levels correlated with BMI and that the 
increased leptin levels promoted pro-inflammatory cytokines and increased autoreactive 
T-cell proliferation while simultaneously inhibiting Treg cell proliferation.72 
One study used Mendelian randomization (MR) to determine the associations between 
BMI, vitamin D status, and MS risk. MR is a type of analysis that utilizes genetic variants 
of a trait (like BMI or vitamin D status) and uses them to ascertain causal associations with 
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a given outcome of interest (like MS). In this 2020 study by Jacobs et al. it was determined 
that genetically increased BMI before the age of 10 is a causal risk factor for MS, 
independent of vitamin D status—a novel finding.73 This study also corroborated other 
studies showing low vitamin D levels were independently associated with increased MS 
risk and that elevated BMI, as a whole, is a risk factor for MS.73  
Because vitamin D is fat-soluble, it has been hypothesized that serum level of 25(OH)D 
and vitamin D reserves could be directly related to an individual’s amount of body fat. 
Indeed, there is a high prevalence of vitamin D insufficiency found in obese individuals.74 
Wortsman et. al found that the baseline serum concentrations of 25(OH)D and parathyroid 
hormone (PTH) in obese patients were significantly lower and higher, respectively, 
compared to control patients.75 This same study also found that the increase in serum 
vitamin D3 concentrations 24 hours after exposure to UVB irradiation via phototherapy 
were 57% lower in obese individuals compared to non-obese individuals (precursor 
molecules in the skin were not significantly different between groups).75 It also revealed a 
highly significant (p=0.007) inverse relationship (r= -0.56) between BMI and peak serum 
vitamin D2 concentrations after an oral dose of 50,000 IU vitamin D2.75 While this study 
shows a weak correlation, similar findings have been demonstrated by other investigators74 
and these results make logical sense—increasing volume with the same amount of vitamin 
D would tend to reduce peak concentration. In a 23-study meta-analysis on the relationship 
between obesity and vitamin D deficiency, it was found that the prevalence of vitamin D 
deficiency was 35% higher in obese individuals compared to non-obese individuals 
independent of age, latitude, or cut-offs to define vitamin D deficiency.76 Another meta-
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analysis that included 21 studies showed that a one point increase in BMI resulted in a 
1.15% reduction in 25(OH)D serum concentration and found that in general, a strong 
inverse relationship between fat volume and serum 25(OH)D concentration exists.77 In 
another study using data from 58 obese adolescents, it was found that serum concentrations 
of 25(OH)D was reduced by 0.46 ± 0.22 ng/mL per 1% increase in body fat mass.78 To 
compound matters, in vitro studies have shown that 1,25(OH)2 D has an inhibitory effect 
on adipogenesis79,80 and that nanomolar concentrations can reduce the accumulation of 
triacyclglycerol by 50% compared to fully differentiated control cells.80  
These studies suggest that obesity and increased BMI reduces the bioavailability of vitamin 
D thus promoting vitamin D deficiency. Since activated vitamin D has been shown in vitro 
to inhibit adipogenesis, vitamin D deficiency may provide an environment prone to 
increased adiposity, creating a viscous cycle with progressively worsening vitamin D 
levels. Ultimately, whether obesity causes the 25(OH)D insufficiency due to a greater flux 
of vitamin D into adipose tissue from the serum or if vitamin D deficiency causes obesity 
through some other mechanism(s) remains to be determined.3,11 Regardless of the 
mechanisms at play it is clear that increases in BMI, specifically increased adiposity, is 
associated with both vitamin D deficiency and increased risk for MS. These studies also 
mirror migrant studies in exposing a similar trend in age-associated risk factors, such that 






The disparity in MS prevalence—and autoimmune diseases in general—between men and 
women has puzzled epidemiologists for decades.  
Genome studies have not revealed MS-associated genes on the X-chromosome.39 As a 
result it is thought that female hormonal physiology may be the influential factor in 
determining MS susceptibility.3,39 The female gender bias of MS (and most other 
autoimmune disorders) has been of notable interest to epidemiologists for decades and 
studies have shown it may be increasing: in the 1980’s the female to male prevalence for 
MS was about 2:181, whereas recent studies indicate a prevalence closer to 3:1.8 MS gender 
bias is not seen before puberty,82 suggesting that either increases in estrogens in females 
add risk or increases in androgens in males decreases risk. It has been shown 
experimentally that vitamin D and estrogens synergistically stimulate favorable 
immunomodulatory effects. Therefore, a widespread vitamin D insufficiency, as is 
occurring, could impact women more than men.47 This is one explanation for why women 
have higher rates of MS compared to men. 
Considering that during pregnancy, especially the third trimester, when estrogens are 
highest, MS relapse rates are low.3,83 Treg levels are also elevated during pregnancy and 
this correlates with the decreased activity of Th1 mediated autoimmune diseases, like 
MS.50 After pregnancy and during menstruation, wherein both circumstances estrogens are 
low, MS symptoms tend to worsen.3 Some studies report exacerbations of MS symptoms 
after menopause,84 the implied cause being a lowering of estrogens that occurs during this 
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time. This can be inferred by trials for predominately estrogen related hormone-
replacement-therapies targeted for postmenopausal women experiencing MS symptoms.85 
Parenthetically, such therapies may not even be safe as a large study consisting of 16,608 
postmenopausal women had to be stopped due to a unsatisfactory risk-benefit of hormone 
therapy.86 However, a 28 study systemic review reported that a potential causal effect of 
estrogen on MS disability is still inconclusive and that relapse rates do not seem to be 
associated with menopause.87 In light of these findings, it would seem that in women higher 
concentrations of estrogens are associated with a reduction of MS symptoms and lower 
concentrations are either not associated with increases in symptoms or are possibly 
associated with increased symptoms. 
While estrogen may or may not be the cause of the female bias, androgens may have merit. 
Since androgen levels are higher in males, on average, and likewise autoimmune disease 
prevalence tends to be lower in males, androgens are speculated to play a protective role 
in MS.84 Immunomodulatory roles of androgens include a shift from Th1 to Th2 
phenotypes, increased production of interleukin 10 (IL-10), and decreased inflammatory 
cytokines IFN-γ and IL-17.84 Furthermore, studies have shown that reduced testosterone is 
a risk factor for MS in both men88 and women.89 In both males90 and females91, testosterone 
decreases as we age, thus this may help explain why relapsing-remitting MS tends to 
transition to progressive MS in the fifth decade of life.92 There is, however, a notable 
decline in clinical and subclinical new disease activity in aging patients in general and is 
strongly related to the age-related phenomenon of immune-senescence of both the innate 
and adaptive immune system.92,93  
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Other in vitro studies have shown increased cytokine secretion in the presence of estrogen 
(IFN-γ, IL-1, IL-10) and decreased secretion in the presence of androgens (IFN-γ, IL-4, 
IL-5).83  This again seems to clash with known cytokine functions in MS. As will be 
discussed in more detail later, IFN-γ is a pro-inflammatory cytokine that is associated with 
MS flare-ups, whereas both IL-10 and IL-4 are anti-inflammatory cytokines that are 
associated with reductions in MS progression. With both estrogens and androgens 
increasing and decreasing both protective and deleterious cytokines, it appears unlikely 
that any clear answer can be obtained through analysis of hormones at this time. Much 
more research in this topic will need to be done if a clear picture of hormonal interactions 
on MS pathophysiology is going to be gleaned. It is also possible that hormonal factors are 
not the main differentiating factor between men and in women in terms of MS risk. Indeed, 
the highly important MS-related CD4+ T-cells are found in higher absolute numbers in 
women compared to men.83  
In humans there is a known positive correlation between BMI and aromatase expression in 
subcutaneous fat.94 Aromatase converts androgens into estrogens, in fact, all estrogens are 
synthesized from androgen precursors.95 Higher levels of aromatase could theoretically 
promote a state of excess estrogen and/or reduce circulating levels of androgens, in either 
case increasing MS risk. A study found that men with MS had about 10% (9.43 +/- 2.04%) 
more body fat percentage compared to men without MS.96 However, no differences were 
found between women with and without MS.96 This study shows that men may be more 
prone to fat-induced risk for MS than women and fits the patterns of aromatase and 
hormonal risk factors.  
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There are a multitude of known factors that increase MS risk that correlate with female 
physiology. Increases in BMI and adiposity are known to be risk factors for MS on their 
own and women tend to have higher fat percentages and have a greater global rate of 
obesity. Aromatase expression increases with adiposity, which could deplete androgens 
and/or promote estrogens, either of which are known hormonal variations that probably 
play a role in MS progression. New research is revealing a mitochondrial component to 
MS that will presumably take many years to fully understand. Together these facts may 




Epstein-Barr Virus (EBV) 
Discovered in 1964, EBV is one of the most widespread viruses in the world, present in all 
populations worldwide and infecting at least 90% of individuals within “the first decades 
of life”.97,98 Belonging to the Herpesviridae family, EBV is a double-stranded DNA virus 
that causes infectious mononucleosis (IM) in up to 40% of adolescents and adults,97 but is 
usually asymptomatic in early childhood.24 EBV infects, activates, and causes clonal 
expansion of B lymphocytes and will persist as a latent infection in these cells.99 In healthy 
individuals, infected cells are kept under control through EBV-specific cytotoxic CD8+ T 
lymphocytes.99 EBV is a known oncogenic virus, recognized as the cause of Burkitt 
lymphoma and is implicated in the pathogenesis of several other cancers.98 EBV is also 
considered to be a major risk factor for developing MS.24,98,100  
Several hypotheses exist to explain the strong association between EBV and MS. Among 
these include:  
1) Molecular mimicry: peripheral activation of both T and B cells against EBV 
antigen may cause cross-reaction with myelin antigens.24 Viral infections may 
lead to MS relapses, providing support for molecular mimicry mechanisms at 
the onset and/or perpetuation of MS.10 
2) Immortalization of B-cells: EBV may induce B-cell immortalization causing 
increased auto-antibody secretion and increased antigen presentation to T-
cells.24 One report found that EBV specific T cells recognize myelin antigens 
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more often than other types of self-antigens and that these cross-reactive T cells 
produce deleterious IFN-γ.24 
3) Direct CNS damage: B-cells in perivascular spaces and meningeal follicles 
infected with EBV may promote CD8+ T-cell responses which subsequently 
damage surrounding tissues.24 
The B-cell is the primary target for EBV infection and at the peak of clinical symptoms 
between .1% to 1% of peripheral blood B cells contain viruses.101 This B-cell invasion 
subsequently triggers an intense CD8+ response.101 This sequence of events nicely ties 
together many of the major players of MS immunology: B-cells, plasma cells, CD4+ T 
cells, and CD8+ T cells. B-cells are antigen presenting cells that possess MHC class II 
receptors capable of activating the all-important CD4+ T cells. When B-cells become 
activated, they differentiate into plasma cells that produce antibodies that are quickly 
becoming recognized as a major factor in MS. The only factor that this does not directly 
account for are the important roles Treg and Breg cells play, which will be explored later. 
Compared to healthy age-matched controls, the prevalence of high titers of anti-EBV 
antibodies in MS patients is significantly greater.24 CD8+ T-cell responses specific for 
EBV are significantly higher in MS patients compared to healthy individuals or those with 
other inflammatory neurological diseases.24 Compared to healthy controls, Epstein-Barr 
nuclear antigen 1 reactive CD4+ memory T cells in MS patients are observed in increased 
numbers, exhibit greater proliferative capacity and IFN-γ production, and have broader 
specificity.24 These findings imply an underlying process that is different in MS patients 
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compared to healthy controls such that the immune system in MS patients is significantly 
more active against EBV. 
A possible mechanism to explain these findings includes a more virulent strain of EBV in 
MS patients. A study from 2015 found that infection with a certain genetic variant of EBV 
correlated with a significant increase in MS risk.102 Unfortunately, this finding provides no 
further insight into the underlying mechanism in EBV-induced MS progression, at least 
not until we learn more about the differences in EBV variant’s mode of infection. 
Regardless, of those infected with EBV only 1 in 500 will develop MS which casts doubt 
that a EBV variant is the sole reason for increased MS risk.97 It is likely that an underlying 
condition/state allows EBV to run rampant (variant or not), thus leading to a higher immune 
response that goes on to cross-react with myelin proteins and subsequently cause MS. 
The latter hypothesis seems likely as there is close to zero risk of developing MS without 
first having been infected with EBV as shown in figure 9.100 Individuals that are determined 
to be EBV-negative had nearly zero risk for developing MS, whereas EBV-positive 
individuals had higher risk, and those that developed clinical IM had 2.3 times higher risk 
of developing MS compared to EBV-infected individuals that had not developed IM. 100,103 
Indeed, a large meta-analysis of studies related to EBV infection induced risk of MS 
conclusively showed that there is indeed an increased risk of MS after EBV infection.100 
However, considering that an EBV infection does not guarantee the development of MS, 




Considering the increased risk IM confers, compared to EBV infections without IM, it 
seems prudent to consider this mechanism.  
 
There seems to be some unknown, yet important factor involved with IM. What is the 
mechanism that causes some individuals to develop IM, while others do not? More 
importantly, what is the mechanism that causes those that developed IM to go on to develop 
MS, while other IM recoverees never do? Interestingly, both IM and MS have similar 
epidemiological patterns as shown below in Table 2.  
Figure 9. Representation of EBV and IM-induced Increase in MS Risk. In 
uninfected individuals, risk for developing MS is essentially zero. Individuals that 
developed IM after EBV infection had about 2.3x greater risk of developing MS 
compared to individuals who did not develop IM after EBV infection. Figure taken from 





Both diseases tend to affect older teens and adults, follow a latitude gradient, and are less 
frequent in black, Asian, and Inuit populations.24 Since EBV infections at a young age do 
not typically result in IM, it is thought that EBV seropositivity at a young age may be 
protective against future MS risk. If this is true, we would expect EBV seropositivity to be 
more prevalent at younger ages in populations that are typically lower risk for MS (Inuits, 
Japanese, etc.).  
In one study from 1984, 87% of Inuit people had anti-EBV antibodies by one year of age.104 
A 2002 study reported that the seropositivity of EBV reported that among 5-9 year-old 
children exceeds 90% in many developing east Asian countries.105 Prior to the 1990s, >80% 
Table 2. Epidemiological Similarities Between Multiple Sclerosis and Infectious 
Mononucleosis. Adapted from (Ascherio & Munger, 2010). 
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of 5-7 year old children in Tokyo were seropositive, but between 1995-1999 that 
seropositivity decreased to 59%.105 It is estimated that <50% of 5-7 year-olds will be 
seropositive by 2006.105 Contrastingly, the Minneapolis-St. Paul metropolitan area in the 
United States, EBV antibodies were not identified in 50% of white children until age 18, 
while 50% of non-white children were antibody positive by age 10.98 This may help explain 
why white populations typically experience higher rates of MS, although this trend may be 
changing. In western countries generally, nearly 50% of children do not acquire EBV as a 
child, thus increasing their likelihood of acquiring IM at an older age and possibly MS.97 
This is thought to contribute to the higher MS rates seen in western countries compared to 
Asian and African countries. IM is also less frequent in developing countries, where it is 
thought that EBV infections tend to occur early in life thus protecting against IM, and 
subsequently MS. 97 
Looking past age of EBV infection, it is also noticeable that many developing countries 
are closer to the equator compared to western countries. Vitamin D production in the skin 
is greatly limited at increasing latitudes as the intensity of UVB rays becomes diminished, 
therefore individuals living closer to the equator produce more vitamin D than others at 
higher latitudes. A study published in 2018 by Perez et al. showed that 25(OH)D may be 
involved in the regulation of EBV replication and reactivation in MS patients, as viral loads 
in serum samples from MS patient were significantly higher in samples with a low level of 
25(OH)D (<13.40 ng/mL, p=0.003).106 Likewise, Japan extends from 20-45 degrees north 
latitude, which may help explain lower MS rates (if the vitamin D hypothesis is to be 
accepted). In contrast, the Inuit people live in much more northern latitudes than MS 
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hotbeds like Europe and the United States, an observation that seems to argue against the 
hypothesis of a protective effect due to latitude-mediated increased vitamin D levels. 
An interesting similarity between the Japanese and Inuit people is their diet, both of which 
heavily rely on fish as a source of food—a rich source of vitamin D. The Japanese diet 
typically consists of high amounts of white rice, seaweeds, vegetables, soybean products, 
and fish, with low amounts of processed meat, nuts, and soft drinks.107 Traditional Inuit 
diet is high in fat and proteins, low in carbohydrates. Caribou, muktuk (whale blubber and 
skin), and salmon-family fish are the most common traditional foods, which are high in 
vitamin D.108 However, recent studies have shown increased consumption of store-bought 
non-nutrient-dense foods with decreased consumption of traditional nutrient-dense 
foods.108–110 Prevalence of MS in Inuit peoples in Alberta, Canada has been found to 
increased 43.6% from 1994-2002, whereas the prevalence in the general population of 
Alberta, Canada has only increased by 21.6% during the same time period.111 It is possible 
increased diagnosis of MS due to greater access to medical care in Inuit populations is the 
cause of this increased prevalence, but it is nonetheless interesting to note the change in 
diet from high to low vitamin D consumption coinciding with an increase in MS.  
In conclusion, EBV and IM clearly increase the risk for developing MS. Whether that risk 






Immunomodulatory Mechanisms of Vitamin D  
With the discovery of VDR expression in nearly all types of immune cells, vitamin D was 
speculated to have a role in immune function decades ago, fueling studies into this topic.112 
Interestingly, many decades ago vitamin D was unknowingly used to treat tuberculosis 
infections with the use of direct sunlight exposure, thought to directly kill the offending 
microbial agent, and with cod liver oil supplements (a rich source of vitamin D).113 
Mounting research has continued to show connections between low levels of vitamin D 
and increased MS risk, as well as a multitude of other autoimmune diseases.114 The 
influence and importance of vitamin D on immune function is well-recognized and is still 
growing.115 Vitamin D deficiency is associated with defective immune function and 
increased risk of developing many conditions including: diabetes mellitus, cardiovascular 
disease, various cancers, and autoimmune and inflammatory diseases, and associated with 
an overall increased risk of mortality.116 Many of the known environmental and genetic 
risk factors associated with MS, a known autoimmune-mediated inflammatory disease, 
implicate vitamin D as having a notable role.  
Vitamin D is a known immunomodulatory agent with a VDRE in the promoter region of 
the most important genetic region (HLA-DRB1 15:01) associated with MS. The proteins 
encoded by this allele are involved in the MHC class II molecules, an important component 
of the immune system that activates CD4+ T-cells. These CD4+ T cells are strongly 
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implicated in the pathogenesis of MS. Furthermore, increased MS risk is associated with a 
homozygotic nonfunctional CYP27B1 gene that encodes for the enzyme that converts 
25(OH)D to the active form, 1,25 (OH)2 D.24 1,25 (OH)2 D has at least three known 
biological functions that are thought to be beneficial in MS: suppression of Th1 and Th17 
differentiation, enhancement of FoxP3+ and IL10+ Treg cell differentiation, and promotion 
of remyelination.117 It is known that 1,25 (OH)2 D decreases production of IL-17 and IL-
21, and increases production IL-10 across several.113  B-cells and the innate immune system 
are also modulated by 1,25 (OH)2 D in protective ways. A quick overview of the functions 
of 1,25 (OH)2 D are depicted below in Figure 10.  
Innate immune cells such as monocytes and dendritic cells express VDR even when 
“resting”, i.e. not activated against a specific antigen, whereas T and B lymphocytes only 
express significant amounts of VDR after activation.20,112 These peripheral blood 
mononuclear cells (PBMCs) express the enzymes 1-alpha-hydroxylase (CYP27B1) and 
24-hydroxylase (CYP24A1) that are important for the activation of 25 (OH)D to 1,25 
(OH)2 D and the inactivation of 1,25 (OH)2 D to 1,24,25 (OH)3 D, respectively.20 Having 
expression of both VDR and critical regulatory enzymes suggests that immune cells are 
able to independently regulate their local 1,25 (OH)2 D concentrations, provided sufficient 





However, the regulation of local 1,25 (OH)2 D concentrations in PBMCs is slightly 
different than its systemic regulation that is principally controlled by the kidneys and 
parathyroid glands. Parathyroid hormone (PTH) is secreted from the parathyroid gland(s) 
in the face of low calcium and/or low magnesium levels. PTH has many functions, but 
Figure 10. Activated Vitamin D Has Many Immunomodulatory Effects. 1,25 
(OH)2 D enhances tolerogenic immune responses via its promotion of Treg and Th2 
subsets, while simultaneously limiting deleterious immune responses through its 
inhibition of Th1 and Th17 subsets. 1,25 (OH)2 D also inhibits B-cell activation and 
has beneficial effects on the innate immune system as well. Figure taken from (Baeke 
et al., 2010). 
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important here is the stimulation of renal CYP27B1 that converts 25 (OH) D to 1,25 (OH)2 
D. The latter product is tightly regulated via negative feedback mechanisms and serum 
concentrations do not significantly change even in the wake of vitamin D 
supplementation.118 In contrast to the kidney proximal tubule cell CYP27B1, the 
“extrarenal” CYP27B1 is found in macrophages and other immune cells.113 This extrarenal 
CYP27B1 is not stimulated by PTH as its renal counterpart is, and its function is dependent 
on circulating levels of 25 (OH) D and various cytokines (IFN-γ, IL-1, or TNF-α).113 In 
macrophages, the 1,25 (OH)2 D inactivating enzyme, CYP24A1, is actually non-functional 
resulting in no negative feedback control of local 1,25 (OH)2 D concentrations.113  
Innate Immune System 
Among the most important gatekeepers of the adaptive immune system are dendritic cells 
and monocytes, both capable of promoting either inflammatory responses to antigen or 
tolerogenic ones.20 1,25 (OH)2 D3 has been shown to promote the innate immune response 
while simultaneously inhibiting the adaptive immune response.15 In monocytes, 1,25 (OH)2 
D inhibits the production of inflammatory cytokines IL-1, IL-6, IL-8, IL-12, and TNF-α.113 
1,25 (OH)2 D inhibits the differentiation and maturation of dendritic cells, as indicated by 
their decreased expression of IL-12, co-stimulatory molecules, and MHC class II surface 
molecules.112,113 This 1,25 (OH)2 D mediated decrease in MHC class II expression has also 
been documented in monocytes and macrophages, resulting in reduced antigen presenting 
ability and a reduction in T-cell stimulatory capacity.112 The loss of MHC-II in monocytes 
cultured with 1,25 (OH)2 D has actually been found to be VDR-dependent, adding strength 
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to the notion of 1,25 (OH)2 D -mediated modulation. This is important because antigen 
presenting cells (APCs) such as monocytes and dendritic cells present antigen to naïve 
CD4+ T-cells via MHC class II molecules in order to activate them. 1,25 (OH)2 D has 
positive chemotaxis effects on monocytes, promotes monocyte-to-macrophage 
differentiation, and promotes macrophage phagocytic and antimicrobial properties.119 The 
latter effects stem from up-regulated expression of Fc receptors, increased oxidative burst, 
and enhanced production of nitric oxide.119 The importance of vitamin D for fighting 
infections is corroborated by the high prevalence of infectious diseases in children with 
rickets which may be the result of impaired macrophage function due to a vitamin D 
deficiency.119 
 Mature dendritic cells will promote an immune response against the presented antigen, 
while immature dendritic cells facilitate tolerance.113,20 1,25 (OH)2 D promotes the 
immature dendritic cell phenotype. Dendritic cells express both CYP27B1 (1-alpha) and 
25-alpha-hydroxylase (CYP2R1), while other immune cells express only CYP27B1.112 
Through their production of IL-12 and IL-23 cytokines, dendritic cells promote deleterious 
Th1 and Th17 phenotypes—1,25 (OH)2 D inhibits production of these cytokines in 
dendritic cells.15,112,20 1,25 (OH)2 D also enhances dendritic cell release of IL-10 and 
CCL22, both of which are involved in the recruitment of Treg cells and promote Th2 
immune responses.15,112,20 In EAE models, 1,25 (OH)2 D significantly decreases disease 
development in wild-type animals, whereas its administration in IL-10 or IL-10 receptor 
knockout animals does not show the same benefit—an indicator of the critical importance 
the IL-10 pathway has in 1,25 (OH)2 D mediated EAE inhibition.24 Indeed, as reviewed by 
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Christakos et al. in 2016, 1,25 (OH)2 D promotes beneficial immune responses through its 
inhibition of IL-12 and IL-17, but requires IL-10 signaling.15 IL-17 is harmful regarding 
inflammatory diseases, but is protective in infectious processes.15 With this in mind, too 
much 1,25 (OH)2 D could potentially leave one susceptible to infection. However, this risk 
may be balanced by its effects on monocytes and macrophages.  
Overall,1,25 (OH)2 D promotes the induction of protective Treg and Th2 cells while 
simultaneously limiting Th1 and Th17 phenotypes, both of which are implicated in MS. 
1,25 (OH)2 D also promotes a tolerogenic dendritic cell induction and function, but this is 
most likely dependent on IL-10 function. 
T-cells 
1,25 (OH)2 D3 is known to reduce IL-17 transcription and Th17 development in general,15 
but its most consistent effect of is the inhibition of Th1 cells.20 In Th1 cells, 1,25 (OH)2 D 
inhibits the secretion of IL-2 and IFN-γ, and in Th17 cells it inhibits secretion of IL-17 and 
IL-21.112 All four of these cytokines are implicated as agents of increased MS risk. IFN-γ 
is the prototypic cytokine in Th1 cells and is often used in studies to measure Th1 
function.20 1,25 (OH)2 D3, through VDR/RXR binding to a IFN-γ silencer region in the 
IFN-γ promoter, has been shown to repress expression of inflammatory cytokine IFN-γ.15 
Most in vitro studies on human CD4+ Th1 cells show that 1,25 (OH)2 D reduces IFN-γ 
secretion and Th1 cell numbers, while some show no effect.20 IL-2 production in both mice 
and human CD4+ T cells is inhibited by 1,25 (OH)2 D, whereas its effect on IL-6 production 
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is inconsistent across studies.20 Multiple groups have found an inverse association between 
serum 25(OH)D concentrations and the fraction of INF-γ+ CD4+ T cells.20  
Additionally, CD8+ T cells exposed to 1,25 (OH)2 D have been shown to have reduced 
levels of IL-17 mRNA, but these results have been inconsistent.20 Treatment with 1,25 
(OH)2 D results in repression of Th1 and Th17 cells, stimulation of Treg cells, and 
diminished inflammation in experimentally induced colitis models.15 
B-cells 
Inactivated/naïve B cells do not express VDR, but once activated the expression of VDR 
and CYP27B1 (1alpha) are upregegulated.20 In vitro exposure of 1,25 (OH)2 D inhibits B-
cell proliferation, differentiation into plasma cells and immunoglobulin secretion (IgG and 
IgM), and induces B-cell apoptosis.20,112,113, In vitro studies have shown that 1,25 (OH)2 D, 
when administered at pharmacological levels, decreases plasma cell conversion and 
antibody production by B cells.24 Breg cells produce more IL-10 with the addition of 1,25 
(OH)2 D, in vitro.20 Many of the above observed effects have yet to be confirmed in vivo 
as studies involving B cells and vitamin D are still in their infancy.  
Regulatory Cells 
1,25 (OH)2 D3 has also been shown to promote Treg cells and to induce Foxp3 transcription 
in Treg cells.15 The prototypic markers for Treg cells are transcription factor Foxp3 and 
IL-10.20 Many human studies show an increase in Foxp3 expression in CD4+ T cells when 
cultured in the presence of 1,25 (OH)2 D.20 There seems to be a positive effect from 1,25 
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(OH)2 D on both the number and function of Foxp3+ IL-10+ Treg cells.20 In vitro, induction 
of IL-10 producing Treg cells is promoted through the administration of either 1,25 (OH)2 
D alone or in combination with dexamethasone.112  As a slight aside, MS patients with 
known helminth infections have been shown to have significantly fewer relapses and 
significantly lower disease activity ratings (determined with  MRI visualization) compared 
to uninfected MS individuals.24 Helminths are a type of parasitic worm that evade detection 
by the host’s immune system by promoting tolerogenic immune responses. The resultant 
MS protection derived from these helminths infections was concomitant with the 
promotion of IL-10 and TGF-β1 secreting regulatory T cells, and induction of CD4+ 
CD25+ FoxP3+ T cells24—remarkably similar to the immunomodulatory effects exhibited 
by vitamin D. 
One in vivo study in healthy volunteers showed that 1,25 (OH)2 D administration (1 ug 
twice daily for 7 days) significantly reduced IL-6 production by PBMCs.20 IL-6 has been 
shown to prevent certain types of Treg cell development.201,25 (OH)2 D reduces CD4+ T 
cell proliferation, expands IL-10 secreting cells, and induces CD4+ CD25+ FoxP3+ 
regulatory T cells.24  
In conclusion, many studies indicate the beneficial immune modulation from either vitamin 
D supplementation or administration of 1,25 (OH)2 D: reduction in the Th1:Th2 ratio, 
stimulation of beneficial Treg cells and IL-10, with the simultaneous reduction of 





Daily Vitamin D Intake Recommendations and Safety: 
There is no consensus on what constitutes “sufficient” vitamin D levels. For example, the 
Institute of Medicine views 25(OH)D levels greater than 20 ng/mL sufficient.120 The 
Endocrine Society’s clinical guidelines, however, define vitamin D deficiency as serum 
25(OH)D levels below 20 ng/ml and vitamin D insufficiency as 25(OH)D levels between 
21-29 ng/ml.53 It is also recommended that those between 0-1 years consume at least 400 
IU of vitamin D/day (IU = 25ng), those 1-70 years at least 600 IU/day, and those 70+ years 
at least 800 IU/day.53 In pregnant and lactating women, at least 600 IU/day is 
recommended. However, whether these recommended minimum intakes of vitamin D are 
enough to provide all of the potential non-skeletal benefits is not known. Actually, to 
consistently achieve the minimal serum concentration of 25(OH)D determined to be 
adequate (30 ng/ml), at least 1000 IU/day of vitamin D may be required in young people 
(0-18), with up to 2000 IU/day needed in adults 19+.53 It is suggested that obese individuals 
of all ages take at least 2-3 time more vitamin D than non-obese individuals of their age 
groups.53  
The highest daily oral intake of vitamin D that poses little-to-no risk of adverse effects for 
most healthy adults remains to be determined.121 However, tolerable upper limits (TUIL) 
of vitamin D have most recently been defined as 1000 IU/ day for infants up to 6 months, 
1500 IU/day for infants 6 months – 1 year, 2500 for children 1-3 years, 3000 for children 
4-8 years, and 4000 for everyone over 8 years.53 These tolerable upper limits have been 
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increased from 2,000 IU/day that was previously considered the maximal safe intake for 
adults.121 A large, in-depth review of vitamin D toxicity studies by Hathock et. al in 2007 
selected 10,000 IU/d as the tolerable upper limit for vitamin D intake and revealed that 
there is little-to-no risk of soft tissue calcification at that limit.121 A higher TUIL could 
probably be defended, as intakes of 20,000 IU/day and even up to 50,000 IU/day did not 
produce serum 25(OH)D levels past the probable intoxication threshold of 200ng/ml.121,122 
However, considering that 10,000 IU is significantly higher than what is known to provide 
all of the known benefits there would seem to be little gained from doing so. 
In fact, exposure to one minimal erythema dose of UV radiation (a slight pinkening of skin 
24 hours post exposure), which can be achieved in just a few minutes while wearing an 
average bathing suit on a summer day, produces an amount of vitamin D equivalent to 
ingesting between 10,000-25,000 IU, depending on skin tone.53,122 However, in a study of 
26 healthy men who work outdoors their serum 25 (OH)D levels at the end of summer 
season were found on average to be equivalent to individuals with a daily oral vitamin D 
intake of about 2,800 IU, with an interquartile range of roughly 1600-3800 IU.123 This 
study reported small, nonsignificant differences in seasonal changes in calcium 
absorption.123 Indeed, no cases of vitamin D intoxication due to sun exposure have ever 
been reported.122  
Vitamin D intoxication from excessive intake is described by hypercalcemia, kidney 
stones, renal calcification, and kidney failure.122 Development of hypercalcemia is the main 
worrisome factor in vitamin D consumption considerations and likewise, is the generally 
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accepted initial sign of vitamin D intoxication.122 One of two mechanisms are thought to 
be the cause: 
1) Direct binding to the VDR by 25(OH)D or vitamin D itself due to extremely 
high concentrations of either directly stimulate pro-calcemic action.122 
However, both molecules are very weak ligands for the VDR, making this 
hypothesis less likely.122 
2) Elevated levels of free 1,25 (OH)2D bind the VDR, stimulating pro-calcemic 
action. The elevation is caused by the 1,25 (OH)2D displacement from the DBP 
due to elevated levels of 25 (OH)D and/or vitamin D.122 This hypothesis is more 
feasible because DBP has 20x greater binding affinity for 25(OH)D than 
1,25(OH2)D.15 
While renal activating mechanisms of 25 (OH) D are indeed responsible for the overall 
circulating pool of 1,25 (OH)2D, this is under very tight regulation. Plasma levels of 
circulating 1,25 (OH)2 D are in the picomolar range, concentrations 1000x lower than 
25(OH)D.18 Theoretically, 25(OH)D, inactive metabolites, and even vitamin D itself could 
bind to the VDR, with much less affinity than 1,25 (OH)2 D, and activate it causing vitamin 
D toxicity. However, such metabolites remain in the bloodstream mainly as the result of 
their greater affinity for DBP.18  
Based on many studies in a number of animal species, plasma 25(OH)D concentrations 
associated with toxicity are essentially always in excess of 150ng/mL.18 In humans, 
hypercalcemia only results when 25(OH)D remains consistently above 150-200ng/mL, but 
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the threshold for toxic symptoms may be closer to 300ng/ml.18 Excluding a handful of rare 
anomalies, the vast majority of vitamin D toxicity cases with hypercalcemia all involve 
daily intakes of vitamin D of at least 40,000IU.124 With this in mind, the proposed upper 
limit of 10,000 IU leaves plenty of room for error.  
People with naturally darker skin may require 3-5 times more sun exposure to 
endogenously synthesize an equivalent amount of vitamin D as individuals with lighter 
skin tones.53 Data obtained from the National Health and Nutrition Examination Survey 
from 2011-2012 was used in a study to determine that 1981 people out of 4962 (39.92%) 
were found to be deficient in vitamin D (<20ng/mL).125 42% of African-American girls 
and women aged 15-49 years throughout United States had less than 15ng/ml 25(OH)D by 
the end of winter.53 Upwards of 50% of Hispanic and African-American adolescents in 
Boston and 48% of “ preadolescent” girls in Maine showed 25(OH)D serum concentrations 
of less than 20 ng/ml indicating that vitamin D deficiency is not limited to individuals with 
darker skin tones.53 The major route in which we receive vitamin D is through the skin 
upon UVB exposure. As reviewed by van Schoor and Lips in 2017, less than 50% of the 
global population, at least in winter, have 25(OH)D levels greater than 20ng/mL.126 This 





Vitamin D may be the common denominator between all of the major environmental 
factors and the most important genetic predisposing factors for MS. Since identical twins 
only have about a 25-30% concordance rate of MS, there must be an environmental factor 
at play. Considering the known correlations between vitamin D and other risk factors for 
MS, as well as its known immunomodulatory mechanisms, it is not unreasonable to 
consider vitamin D playing a significant role in disease initiation and/or progression. Of all 
the environmental risk factors—aside from low vitamin D itself—EBV is by far the most 
heavily supported and tightly linked risk factor for MS. EBV infects B cells and promotes 
inflammatory responses in these cells. Infected B-cells become activated, releasing more 
proinflammatory cytokines and secreting immunoglobulins. Both of these factors have 
been implicated in MS risk. 
Furthermore, B cells are APCs with MHC class II molecules that present to the all-
important CD4+ T-cell. This causes CD4+ T cells to become activated and promote 
additional inflammatory effects. Infected B-cells can also present EBV antigen via MHC 
class I molecules to CD8+ T-cells which are also implicated in MS. Viral and bacterial 
antigens have been known to cause cross-reactions through molecular mimicry 
mechanisms. Finally, the risk for MS is essentially zero for individuals who have never 
been infected with EBV making it highly likely that EBV plays a considerable role in MS, 
or at least in its initiation. However, over 90% of the world population has been infected 
with EBV at some point. If EBV infection itself was the main cause, it does not make sense 
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that there would be such a disparity between EBV infections and MS cases (500:1). 
Acquiring IM increases the risk of developing MS by 2-3x but does not guarantee its 
development, casting more doubt on EBV being the main cause of MS. This fact indicates 
that there is another important factor at play that needs to be considered. Based on genetic 
considerations and environmental factors, this other important factor is most likely vitamin 
D.  
Possible explanations for this may include: 
1) People that develop IM are predisposed to develop MS regardless of infection 
or vitamin D status, i.e., developing IM does nothing mechanistically to increase 
MS risk. 
2) Acquiring IM increases the risk of developing vitamin D deficiency, thus 
increasing risk to develop MS. 
3) People that become vitamin D deficient are predisposed to develop MS 
regardless of infection, i.e., vitamin D deficiency does nothing mechanistically 
to increase MS risk. 
4) People that are vitamin D deficient are more likely to develop IM, thus 
increasing risk to develop MS. 
 
Hypotheses 1 seems unrealistic as B-cell activation in general creates an environment 
essentially identical to the internal environments of MS patients. EBV is known to attack 
and activate B cells. Hypothesis 2 is unlikely as no known mechanisms exist that could 
explain EBV directly inhibiting vitamin D intake/absorption or its production in the skin. 
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Hypothesis 3 is unlikely as many, if not all, of the inflammatory conditions known to occur 
in MS are also known to be reduced through high dose vitamin D supplementation or 
through 1,25 (OH)2 D treatment.  
This leaves hypothesis 4 as the most likely explanation to account for all of the many risk 
factors for MS: genetic and environmental. Vitamin D represses B-cell differentiation into 
plasma cells, reduces MHC II expression, and promotes apoptosis of B cells—in other 
words, vitamin D does the exact opposite of what EBV does to the B cell. Vitamin D also 
promotes tolerogenic mechanisms that may or may not be associated with EBV infections. 
Considering these immunomodulatory mechanisms, it is no wonder why lower vitamin D 
levels correlate with higher EBV load and with higher risk of MS. 
Vitamin D is also known to correlate with increased MS risk on its own, but this may be 
misleading as nearly every person in the world has been infected with EBV. This means 
that vitamin D risk assessments are probably always paired with the underlying risk 
associated with EBV. This is true for other risk factors as well: genetics, latitude, obesity, 
biologic sex, etc. However, each one of these risk factors has a logical and evidence-based 
connection to vitamin D.  
It is interesting to consider that immune cells may not only require 1,25 (OH)2 D to function 
but may need concentrations much higher than could safely be tolerated systemically. Why 
else would the critical components of vitamin D action—VDR, CYP27B1, and 
CYP24A1—be independently regulated in immune cells and potentially allow for higher 
local 1,25 (OH)2 D concentrations compared to systemic levels? As the unregulated 
extrarenal CYP27B1 requires adequate 25(OH)D levels to function optimally, vitamin D 
	 	 	
	69	
deficiency could through mass action equilibrium limit local 1,25 (OH)2 D production and 
subsequently impair immune cell function. 
Knowing that the vast majority of people in the U.S. and around the world are deficient in 
vitamin D, as defined by our current vitamin D standards, it would be extremely beneficial 
to increase the minimal dietary recommendation from ~800 IU vitamin D/day to at least 
2000 IU, as this is the value that is required for individuals to maintain their 25 (OH)D 
concentrations above 30 ng/mL. It is also possible that the currently defined threshold of 
sufficient vitamin D at 30 ng/mL is too low.  
Research in the area of defining adequate nutrition needs has been minimal at best. It 
implicitly assumes that if no disease is present at a given value or concentration, then that 
must be the correct or adequate level. It also assumes that the levels seen in humans today 
are the same levels seen 200 or more years ago. Humans have not evolved, at least not 
appreciably so, in this timeframe but our way of life most definitely has. Humans 
collectively spend more time indoors than any time in history; thus, our vitamin D levels 
may too be lower than any time in history. Just because the negative symptoms that we 
know to look for (rickets, osteomalacia, bone fractures) tend to be seen less in individuals 
with concentrations above 30ng/mL does not mean there are no symptoms or disease 
processes taking place related to low vitamin D. For example, numerous studies have 
suggested that the lower limit of serum 25(OH)D required to control MRI activity and 
clinical disease symptomology in MS patients is approximately 40 ng/mL.120 It may happen 
to be that we simply do not know to look for these diseases in relationship to vitamin D 
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levels. Perhaps autoimmune diseases are these “hidden” diseases—perhaps not. More 
research will need to be done to determine this.  
What can be stated with confidence, however, is the immense benefit vitamin D has on 
many systems in the body and especially on the immune system. Knowing that vitamin D 
has so many numerous benefits, it may be beneficial to increase the minimum daily 
recommendation of vitamin D to 5,000 IU, while maintaining the TUIL at the current figure 
of 10,000 IU/day. Even at 5,000 IU minimum intake every day, there is almost no known 
risk for intoxication of vitamin D. There have been essentially zero confirmed cases of 
vitamin D intoxication at serum 25(OH)D levels less than 200 ng/ml—levels requiring at 
least 20,000 IU/day and quite possibly 50,000 IU/day. At 5,000 IU/day individuals would 
be maximizing the known benefits of vitamin D and increasing the likelihood of obtaining 
the other benefits of vitamin D that are surely there, but not known yet, while still 
maintaining an abundance of caution as the TUIL is much higher by even the most 
conservative of looks.  
In conclusion, there is strong evidence, from both epidemiologic and laboratory studies, 
indicating a relationship between vitamin D deficiency and increased MS risk. Based on 
the known protective immunomodulatory effects of vitamin D supplementation and/or 1,25 
(OH)2 D treatment, coupled with their favorable risk-benefit profile in patients with MS, 
there is a compelling reason for researchers to continue and expand large, comprehensive 
clinical trials to determine the efficacy of vitamin D supplementation and/or 1,25 (OH)2 D 
treatment for MS patients. At the very least, dietary requirements for vitamin D should be 
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raised, especially among darker skinned individuals who may be at greater risk for 
developing vitamin D deficiency. There is strong evidence indicating the safety of vitamin 
D supplementation and the probable beneficial effects such supplementation has in MS 
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